Hsp90 inhibition protects brain endothelial cells against LPS-induced injury.
Mohammad A UddinMohammad S AkhterKhadeja-Tul KubraNektarios BarabutisPublished in: BioFactors (Oxford, England) (2022)
Dysfunction of the blood-brain barrier (BBB) endothelium increases infiltration of lymphocytes and innate immune cells in the brain, leading to the development of neurological disorders. Heat shock protein 90 (Hsp90) inhibitors are anti-inflammatory agents and P53 inducers, which reduce the production of reactive oxygen species (ROS) in a diverse variety of human tissues. In this study, we investigate the effects of those compounds in LPS-induced brain endothelial inflammation, by utilizing human cerebral microvascular endothelial cells (hCMEC/D3). Our results suggest that Hsp90 inhibitors suppress inflammation by inhibiting the LPS-induced signal transducer and activator of transcription 3 (STAT3); and P38 activation. Moreover, those compounds reduce the P53 suppressors murine double minute 2 (MDM2) and murine double minute 4 (MDM4). Immunoglobulin heavy chain binding protein/glucose-regulated protein 78 (BiP/Grp78)-a key element of endothelial barrier integrity-was also increased by Hsp90 inhibition. Hence, we conclude that application of Hsp90 inhibitors in diseases related to BBB dysfunction may deliver a novel therapeutic possibility in the affected population.
Keyphrases
- lps induced
- heat shock protein
- endothelial cells
- inflammatory response
- heat shock
- oxidative stress
- reactive oxygen species
- high glucose
- cerebral ischemia
- binding protein
- resting state
- white matter
- blood brain barrier
- vascular endothelial growth factor
- immune response
- functional connectivity
- anti inflammatory
- heat stress
- gene expression
- transcription factor
- nitric oxide
- subarachnoid hemorrhage
- cell death
- nuclear factor
- signaling pathway
- peripheral blood
- type diabetes
- small molecule
- brain injury